Neoplastic Process
Revolutions KRAS drugs appear competitive in several lung cancer settings
KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines
Takeda announces handful of pipeline cuts in effort to pivot resources
Takeda, pipeline, restructuring, Solid Neoplasm, pivot resources
Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff
Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%
Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC
Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%
Recursion’s homegrown assets hardest hit in AI-discovered pipeline cull
Recursion, homegrown, assets
Exact Sciences plans ‘transformative year’ with 3 cancer test debuts
Science, MRD, Exact brand biomedical or dental material, Hypersensitivity
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap
Truqap, AstraZeneca, Television, Faslodex, Malignant neoplasm of breast
AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
Cancer research, AACR 2025, Marengo Therapeutics, BriaCell, oncology advancements, colorectal cancer, breast cancer, immunotherapy
AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer
Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability